Business
Capital Markets Event
Capital Markets Event.
About this update from Convatec Group Plc
[{"type":"text","content":"\n \n \n \n 17 November 2022\n \n \n \n \n Convatec Group Plc\n \n \n \n \n Capital Markets Event\n \n \n \n \n \n \n Convatec will host a Capital Markets Event this afternoon, 17 November 2022.\n \n \n \n \n \n Convatec's Executive Leadership Team, including Chief Executive Officer, Karim Bitar, and Chief Financial Officer, Jonny Mason, will present the next phase of Convatec's FISBE strategy and the Group's future growth opportunities. \n \n \n \n \n \n The team will provide insight into how the Group intends to deliver sustainable organic revenue growth of 4-6% per annum and adjusted operating profit margin expansion into the mid-20s over the medium-term. In delivering these targets, the Group also expects to achieve double-digit EPS and Free Cash Flow CAGR.\n \n \n \n \n \n The presentations will provide detail into:\n \n \n - \n The attractive chronic care markets the Group operates in and Convatec's leading positions across key geographies\n \n \n - \n The next phase of the Group's FISBE strategy and how the five pillars will evolve to:\n \n \n ·\n Focus\n \n on\n strengthening customer loyalty in\n key markets and categories\n \n \n \n ·\n Innovate\n \n to increase vitality and velocity of\n trusted medical solutions\n \n \n \n ·\n Simplify\n \n to improve productivity across\n our organisation\n \n \n \n ·\n Build\n \n and embed\n mission-critical capabilities\n and winning culture\n \n \n \n ·\n Execute\n \n with excellence\n while\n integrating ESG\n \n \n \n - \n The growth strategies and opportunities for each of the Group's categories - Advanced Wound Care, Ostomy Care, Infusion Care and Continence Care - and how each will improve the customer experience, enhance its portfolio and drive productivity\n \n \n - \n How the Group intends to improve its operating profit margin by:\n \n \n ·\n strengthening mix across and within categories\n \n \n ·\n driving simplification and productivity across commercial, Global Quality & Operations and G&A\n \n \n - \n The attractive financial qualities of the Group, its cash generative nature, and the Group's capital allocation framework\n \n \n \n \n \n On 10 November 2022 the Group published its 10-month trading statement which highlighted continued good momentum in the business. The Group upgraded its 2022 ...